These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. The Advantages of New Multimodality Imaging in Choosing the Optimal Management Strategy for Patients with Hypertrophic Cardiomyopathy. Anghel L; Stătescu C; Șerban IL; Mărănducă MA; Butcovan D; Clement A; Bostan M; Sascău R Diagnostics (Basel); 2020 Sep; 10(9):. PubMed ID: 32961665 [TBL] [Abstract][Full Text] [Related]
9. An evaluation of mavacamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy in adults. Dong T; Nissen S; Ospina S; Desai MY Expert Rev Cardiovasc Ther; 2023 Jan; 21(1):5-13. PubMed ID: 36522857 [TBL] [Abstract][Full Text] [Related]
10. Genetics of hypertrophic cardiomyopathy after 20 years: clinical perspectives. Maron BJ; Maron MS; Semsarian C J Am Coll Cardiol; 2012 Aug; 60(8):705-15. PubMed ID: 22796258 [TBL] [Abstract][Full Text] [Related]
11. Hypertrophic cardiomyopathy: an up-to-date snapshot of the clinical drug development pipeline. Tamargo J; Tamargo M; Caballero R Expert Opin Investig Drugs; 2022 Oct; 31(10):1027-1052. PubMed ID: 36062808 [TBL] [Abstract][Full Text] [Related]
12. Novel Approach Targeting the Complex Pathophysiology of Hypertrophic Cardiomyopathy: The Impact of Late Sodium Current Inhibition on Exercise Capacity in Subjects with Symptomatic Hypertrophic Cardiomyopathy (LIBERTY-HCM) Trial. Olivotto I; Hellawell JL; Farzaneh-Far R; Blair C; Coppini R; Myers J; Belardinelli L; Maron MS Circ Heart Fail; 2016 Mar; 9(3):e002764. PubMed ID: 26915375 [TBL] [Abstract][Full Text] [Related]
14. Hypertrophic Cardiomyopathy: Diverse Pathophysiology Revealed by Genetic Research, Toward Future Therapy. Hayashi T Keio J Med; 2020 Dec; 69(4):77-87. PubMed ID: 32224552 [TBL] [Abstract][Full Text] [Related]
15. Familial Hypertrophic Cardiomyopathy: Diagnosis and Management. Litt MJ; Ali A; Reza N Vasc Health Risk Manag; 2023; 19():211-221. PubMed ID: 37050929 [TBL] [Abstract][Full Text] [Related]
16. Mavacamten: a novel small molecule modulator of β-cardiac myosin for treatment of hypertrophic cardiomyopathy. Tower-Rader A; Ramchand J; Nissen SE; Desai MY Expert Opin Investig Drugs; 2020 Nov; 29(11):1171-1178. PubMed ID: 32897741 [TBL] [Abstract][Full Text] [Related]
17. Prospects for remodeling the hypertrophic heart with myosin modulators. Sewanan LR; Shimada YJ Front Cardiovasc Med; 2022; 9():1051564. PubMed ID: 36330009 [TBL] [Abstract][Full Text] [Related]
18. Treating a Structural Heart Disease Using a Non-structural Approach: Role of Cardiac Pacing in Hypertrophic Cardiomyopathy. Albano BB; Fadreguilan EC; Chua JM; Ho J; Medrano AB Cardiol Res; 2017 Feb; 8(1):20-25. PubMed ID: 28275421 [TBL] [Abstract][Full Text] [Related]